Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director
Pharming Group has announced its 2025 Annual General Meeting (AGM) scheduled for June 11, 2025. The company has nominated Dr. Elaine Sullivan as a new Non-Executive Director for a four-year term, following the departure of Deborah Jorn and Steven Baert.
The AGM agenda includes the reappointment of Jabine van der Meijs and Leonard Kruimer as Non-Executive Directors, and Deloitte Accountants as external auditor. The Board seeks authorization for share issuance and repurchase.
Dr. Sullivan brings extensive pharmaceutical and biotech experience, currently serving on boards of Zealand Pharma and hVIVO. Her background includes senior roles at Eli Lilly and AstraZeneca, plus board positions at IP Group, Evotec AG, and other companies. She holds a PhD in Molecular Virology and BSc in Molecular Biology.
Pharming Group ha annunciato la convocazione della sua Assemblea Generale Annuale (AGA) per l'11 giugno 2025. La società ha nominato Dr.ssa Elaine Sullivan come nuova Direttrice Non Esecutiva per un mandato quadriennale, in seguito alle dimissioni di Deborah Jorn e Steven Baert.
All'ordine del giorno dell'AGA figurano la riconferma di Jabine van der Meijs e Leonard Kruimer come Direttori Non Esecutivi, e la nomina di Deloitte Accountants come revisore esterno. Il Consiglio chiederà l'autorizzazione per l'emissione e il riacquisto di azioni.
La Dr.ssa Sullivan porta con sé una vasta esperienza nel settore farmaceutico e biotecnologico, attualmente siede nei consigli di amministrazione di Zealand Pharma e hVIVO. Il suo percorso include ruoli dirigenziali in Eli Lilly e AstraZeneca, oltre a incarichi nei CDA di IP Group, Evotec AG e altre società. È in possesso di un dottorato in Virologia Molecolare e di una laurea in Biologia Molecolare.
Pharming Group ha anunciado su Junta General Anual (JGA) programada para el 11 de junio de 2025. La compañía ha nominado a la Dra. Elaine Sullivan como nueva Directora No Ejecutiva por un mandato de cuatro años, tras la salida de Deborah Jorn y Steven Baert.
La agenda de la JGA incluye la reelección de Jabine van der Meijs y Leonard Kruimer como Directores No Ejecutivos, y a Deloitte Accountants como auditor externo. La Junta solicitará autorización para la emisión y recompra de acciones.
La Dra. Sullivan aporta amplia experiencia en farmacéutica y biotecnología, actualmente forma parte de los consejos de Zealand Pharma y hVIVO. Su trayectoria incluye cargos senior en Eli Lilly y AstraZeneca, además de puestos en los consejos de IP Group, Evotec AG y otras compañías. Posee un doctorado en Virología Molecular y una licenciatura en Biología Molecular.
Pharming Group는 2025년 6월 11일로 예정된 2025년 연례 주주총회(AGM)를 발표했습니다. 회사는 Deborah Jorn과 Steven Baert의 퇴임에 따라 Dr. Elaine Sullivan을 4년 임기의 신규 비상임 이사로 지명했습니다.
AGM 안건에는 Jabine van der Meijs와 Leonard Kruimer의 비상임 이사 재선임 및 Deloitte Accountants의 외부 감사 선임이 포함되어 있습니다. 이사회는 주식 발행 및 자사주 매입 권한을 요청할 예정입니다.
Dr. Sullivan은 제약 및 바이오테크 분야에서 풍부한 경험을 보유하고 있으며, 현재 Zealand Pharma와 hVIVO 이사회에서 활동 중입니다. 그녀는 Eli Lilly와 AstraZeneca에서 고위직을 역임했으며, IP Group, Evotec AG 등 여러 회사의 이사회에도 참여했습니다. 분자 바이러스학 박사 학위와 분자 생물학 학사 학위를 보유하고 있습니다.
Pharming Group a annoncé la tenue de son Assemblée Générale Annuelle (AGA) prévue pour le 11 juin 2025. La société a nommé Dr Elaine Sullivan en tant que nouvelle administratrice non exécutive pour un mandat de quatre ans, suite au départ de Deborah Jorn et Steven Baert.
L'ordre du jour de l'AGA comprend la réélection de Jabine van der Meijs et Leonard Kruimer en tant qu'administrateurs non exécutifs, ainsi que la nomination de Deloitte Accountants en tant qu'auditeur externe. Le Conseil sollicitera une autorisation pour l'émission et le rachat d'actions.
Dr Sullivan apporte une vaste expérience dans les secteurs pharmaceutique et biotechnologique, siégeant actuellement aux conseils d'administration de Zealand Pharma et hVIVO. Son parcours inclut des postes de direction chez Eli Lilly et AstraZeneca, ainsi que des mandats au sein des conseils d'administration d'IP Group, Evotec AG et d'autres entreprises. Elle est titulaire d'un doctorat en virologie moléculaire et d'une licence en biologie moléculaire.
Pharming Group hat seine Jahreshauptversammlung (HV) für den 11. Juni 2025 angekündigt. Das Unternehmen hat Dr. Elaine Sullivan als neues nicht geschäftsführendes Vorstandsmitglied für eine vierjährige Amtszeit nominiert, nachdem Deborah Jorn und Steven Baert ausgeschieden sind.
Die Tagesordnung der HV umfasst die Wiederbestellung von Jabine van der Meijs und Leonard Kruimer als nicht geschäftsführende Direktoren sowie Deloitte Accountants als externe Prüfer. Der Vorstand strebt eine Genehmigung zur Ausgabe und zum Rückkauf von Aktien an.
Dr. Sullivan bringt umfassende Erfahrung in der Pharma- und Biotechnologiebranche mit und ist derzeit Mitglied der Aufsichtsräte von Zealand Pharma und hVIVO. Ihre Laufbahn umfasst leitende Positionen bei Eli Lilly und AstraZeneca sowie Aufsichtsratsmandate bei IP Group, Evotec AG und weiteren Unternehmen. Sie besitzt einen Doktortitel in Molekularvirologie und einen Bachelor in Molekularbiologie.
- Appointment of Dr. Elaine Sullivan brings extensive pharmaceutical and biotech industry experience, including senior roles at Eli Lilly and AstraZeneca
- Dr. Sullivan's expertise in drug development, business development, and fund investments strengthens the board's capabilities
- Dr. Sullivan's current board positions at Zealand Pharma and hVIVO demonstrate active involvement in biotech and clinical research sectors
- Loss of two Non-Executive Directors (Deborah Jorn and Steven Baert) who are not seeking reappointment
Leiden, the Netherlands, April 30, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that the Company’s 2025 Annual General Meeting of Shareholders (the “AGM”) will be held on Wednesday June 11, 2025, at 14:00 CEST. The Notice to Convene, Explanatory Notes, Proxy and other meeting documents for the AGM can be found on the Company’s website under Investors/Shareholder Meetings.
The Board of Directors has decided to nominate Dr. Elaine Sullivan at the AGM for the appointment as a new Non-Executive Director for a term of four years. The terms of Mrs. Deborah Jorn and Mr. Steven Baert are scheduled to expire at the AGM and they are not available for reappointment.
The agenda of the AGM also includes the reappointments of Mrs. Jabine van der Meijs and Mr. Leonard Kruimer as Non-Executive Directors, the proposal to reappoint Deloitte Accountants B.V. as the external auditor of the Company for the financial year 2025, and the renewal of the authorizations for the Board of Directors to issue shares (including rights to acquire shares), and to repurchase shares.
The AGM will be held at the Corpus Congress Centre, Willem Einthovenstraat 1, 2342 BH in Oegstgeest, the Netherlands, and will be webcast live.
Profile
Dr. Elaine Sullivan (date of birth: February 6, 1961, British and Irish citizen) is a senior executive, with a successful track record in developing novel medicines, business development, fund investments and start-ups. Dr. Sullivan has international experience in the pharmaceutical and biotech industry, having lived and worked in Ireland, UK, Switzerland, and the US, delivering novel drug projects, commercial partnerships and implementing breakthrough technologies.
Dr. Sullivan has served as Non-Executive Director at Zealand Pharma A/S (listed on NASDAQ Copenhagen, “ZEAL”), a biotechnology company focused on the discovery and development of peptide-based medicines, since 2024. She has also served as Senior Non-Executive Director at hVIVO, previously known as Open Orphan plc, listed on the London Stock Exchange AIM market (“HVO”) since 2020. hVIVO is a contract research organization which is a world leader in human challenge clinical trials.
Prior thereto, Dr. Sullivan gained global leadership experience, including membership of the senior global R&D management teams at Eli Lilly and Company (US) and AstraZeneca (UK), and also served as Non-Executive Director at various public companies, including IP Group plc, Evotec AG, Active Biotech AB and Nykode Therapeutics ASA, including membership in audit, remuneration, ESG and nomination committees.
Dr. Sullivan holds a PhD in Molecular Virology (University of Edinburgh) and a BSc (Hons) in Molecular Biology (University of Glasgow, UK).
The resume of Dr. Sullivan has been uploaded as part of the meeting documents for the AGM. Dr. Sullivan will introduce herself to our shareholders during the AGM.
About Pharming Group N.V.
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are commercializing and developing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.
For more information, visit www.pharming.com and find us on LinkedIn.
Inside Information
This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
For further public information, contact:
Pharming Group, Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com
FTI Consulting, London, UK
Simon Conway/Alex Shaw/Amy Byrne
T: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl
Attachment
FAQ
When is Pharming Group (PHARM) 2025 Annual General Meeting and where will it be held?
Who is Dr. Elaine Sullivan, the new Non-Executive Director nominee for Pharming (PHARM)?
What key proposals are on the agenda for Pharming Group's (PHARM) 2025 AGM?
Which Board members are leaving Pharming Group (PHARM) at the 2025 AGM?
What share-related authorizations are being proposed at Pharming's (PHARM) 2025 AGM?
